| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532; 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:Moexiprilat
CAS:103775-14-0
Package:50Mg,5Mg
|
| Company Name: |
Chemsky (shanghai) International Co.,Ltd
|
| Tel: |
021-50135380 |
| Email: |
shchemsky@sina.com |
| Products Intro: |
Product Name:Moexiprilat-d5;(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-(phenyl-d5)propyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid; [3S-[2[R*(R*)],3R*]]-2-[2-[(1-
Carboxy-3-(phenyl-d5)propyl)aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid; RS 10029
CAS:103775-14-0
Purity:98+% Package:1Mg;5Mg;10Mg;50Mg;100Mg;500Mg
|
| Company Name: |
Cato Research Chemicals Inc.
|
| Tel: |
020-81960175 |
| Email: |
min.he@cato-chem.com |
| Products Intro: |
Product Name:Moexiprilat
CAS:103775-14-0
Purity:95% Package:25Mg, 50Mg
|
|
| | MOEXIPRILAT HYDRATE Basic information |
| Product Name: | MOEXIPRILAT HYDRATE | | Synonyms: | (3S)-2-[(2S)-2-{[(1S)-1-carboxy-3-(2,3,4,5,6-pentahydrogeniophenyl)propyl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid;[3S-[2[R*(R*)],3R*]]-2-[2-[(1-
Carboxy-3-phenylpropyl)aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid;RS 10029;(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-(phenyl-d5)propyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid;[3S-[2[R*(R*)],3R*]]-2-[2-[(1-
Carboxy-3-(phenyl-d5)propyl)aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid;Moexipril Related CoMpound A;2-[2-(1-Carboxy-3-phenyl-propylamino)-propionyl]-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic Acid Hydrate | | CAS: | 103775-14-0 | | MF: | C25H30N2O7 | | MW: | 470.51 | | EINECS: | | | Product Categories: | All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics;Chiral Reagents | | Mol File: | 103775-14-0.mol |  |
| | MOEXIPRILAT HYDRATE Chemical Properties |
| Melting point | 145-1700C | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | DMSO: soluble
Methanol: soluble | | Major Application | pharmaceutical | | InChIKey | CMPAGYDKASJORH-YSSFQJQWSA-N | | SMILES | N2([C@@H](Cc3c(cc(c(c3)OC)OC)C2)C(=O)O)C(=O)[C@@H](N[C@@H](CCc1ccccc1)C(=O)O)C |
| WGK Germany | WGK 3 | | HS Code | 2933497050 | | Storage Class | 13 - Non Combustible Solids |
| | MOEXIPRILAT HYDRATE Usage And Synthesis |
| Chemical Properties | White Crystalline Solid | | Uses | Analogue of Quinapril | | Uses | Angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of Quinapril. Antihypertensive. | | Uses | Moexiprilat is an angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of Quinapril. Antihypertensive. | | References | [1] O EDLING. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 275 2: 854-863.
[2] RYAN T. CAMERON . Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)[J]. Biochemical pharmacology, 2013, 85 9: Pages 1297-1305. DOI: 10.1016/j.bcp.2013.02.026
[3] C GROHÉ. Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth.[J]. Journal of Hypertension, 1998, 16 3: 377-384. DOI: 10.1097/00004872-199816030-00015
[4] VAN EICKELS MARTIN. The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats[J]. European Journal of Heart Failure, 2005, 7 7: 1079-1084. DOI: 10.1016/j.ejheart.2005.03.004 |
| | MOEXIPRILAT HYDRATE Preparation Products And Raw materials |
|